Evommune, Inc.
EVMN
Get informed when a big investor buys or sells
+ FollowMarket Cap$350.22M
Close$
$-24.35
376.7% downside
Current Fair Value
376.7% downsideOvervalued by 376.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $350.22 Million |
|---|---|
| Enterprise Value | $298.30 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.18 |
| Beta | 0.96 |
| Outstanding Shares | 36,135,644 |
Return
| Return on Equity | -34.10% |
|---|---|
| Return on Assets | -31.35% |
| Return on Invested Capital | -35.52% |
Valuation & Multiples
| P/E Ratio | -3.41 |
|---|---|
| PEG | -2.48 |
| Price to Sales | - |
| Price to Book Ratio | 1.26 |
| Enterprise Value to Revenue | 29.83 |
| Enterprise Value to EBIT | -2.95 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.66
Average shareholder expectationRevenue Estimate
$1.33 M
Average shareholder expectationNext Earnings Call
Expected Date
October 16, 2026
EPS Estimate
$-0.82
Average shareholder expectationRevenue Estimate
$333,330
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.4158▲ 141.58% |
|---|---|
| Total Calls | 442,000▲ Infinity% |
| Total Puts | 625,800▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 96.08%▼ 6.61% |
|---|---|
| Total Invested | $464.31M▼ 41.48% |
| Investors Holding | 116▲ 32.00% |
ESG Score
No data
About Evommune, Inc.
45 employees
CEO: Luis C. Pena Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic sponta...